EN
Thrombophilic gene variants in patients with coronary artery disease and myocardial infarction
Abstract
Background and aim: Coronary artery disease (CAD) and myocardial infarction (MI) are cardiovascular diseases that occur due to atherosclerosis (plaque formation) or atherosclerotic obstruction of the coronary arteries. Their genetic basis has been under investigation for a long time, and common variant studies link different genetic loci with these diseases. In this study, we investigated the possible association of coronary artery disease and myocardial infarction with thrombophilic gene variants, including MTHFR C677T and A1298C, Beta fibrinogen -455G/A, Factor XIIIV34L and PAI-1 4G/5G single nucleotide polymorphisms (SNPs).
Methods: A total of 128 people (64 patients and 64 controls) were included in the study. Genomic DNA was isolated using the EZ1 blood mini kit. The DNA was amplified and PCR was performed using the PyroMark PCR Kit (Qiagen, Germany). Pyrosequencing reaction was completed by processing with PyroMark Q24 instrument.
Results: We found that the PAI-1 4G/5G polymorphism and the 4G allele were significantly associated with coronary artery disease and myocardial infarction (P= 0.01). Although mutant variants were higher in patients, no statistically significant difference was observed between the patient and control groups in terms of FXIII, Beta-fibrinogen and MTHFR variants.
Conclusions: It is clear that the PAI-1 4G allele and the 4G/4G genotype have a significant contribution to the development of coronary artery disease and ultimately myocardial infarction. Prophylactic treatment should be considered in patients with this variant.
Keywords
References
- 1. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-23.
- 2. Buntsma N, van der Pol E, Nieuwland R, Gąsecka A. Extracellular Vesicles in Coronary Artery Disease Adv Exp Med Biol. 2023;1418:81-103.
- 3. Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial Infarction: Symptoms and Treatments. Cell Biochem Biophys. 2015 Jul;72(3):865-7.
- 4. Truesdell AG, Alasnag MA, Kaul P, Rab ST, Riley RF, Young MN, et al. Intravascular Imaging During Percutaneous Coronary Intervention: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023;81(6):590-605.
- 5. Park HS, Sung JH, Ryu CS, Lee JY, Ko EJ, Kim IJ, The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population. J Pers Med. 2020 Nov 28;10(4):257.
- 6. Abd El-Aziz TA, Rezk NA. Relation of PAI-1 and TPA genes polymorphisms to acute myocardial infarction and its outcomes in Egyptian patients. Cell Biochem Biophys. 2015;71(1):227-34.
- 7. Mlynarska A, Waszyrowski T, Kasprzak JD. Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI-1 gene. J Thromb Haemost. 2006;4(6):1361-6.
- 8. Li L, Yu H, Zhang H, Wang J, Hu W. Association between MTHFR C677T polymorphism and risk of coronary artery disease in the Chinese population: meta-analysis. Herz. 2022;47(6):553-563.
Details
Primary Language
English
Subjects
Multimorbidity
Journal Section
Research Article
Authors
Publication Date
December 31, 2023
Submission Date
October 9, 2023
Acceptance Date
December 25, 2023
Published in Issue
Year 2023 Volume: 45 Number: 4